Figure 1.

The role of biomarker tools and plasma AR status in different clinical states of prostate cancer. A clinical states framework for clinical practice, clinical research, and biomarker tools in prostate cancer with a graphical representation of tumor burden, plasma DNA levels, clonal heterogeneity, and utility of plasma AR status over time and in response to therapy. Abbreviations: ADT, androgen deprivation therapy; AR, androgen receptor; CRPC, castration-resistant prostate cancer; ctDNA, circulating tumor DNA; HSPC, hormone-sensitive prostate cancer; RT, radiotherapy.